Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2017 pubmed

Circulating cathelicidin LL-37 in adult patients with pulmonary infectious diseases.

Majewski. Karol K; Żelechowska. Paulina P; Brzezińska-Błaszczyk. Ewa E

Key Findings

  • TB patients had the highest serum LL‑37 levels (≈14 ng/mL)
  • Pneumonia patients also showed elevated LL‑37 (≈8‑10 ng/mL) versus healthy controls (≈1.8 ng/mL)
  • Higher LL‑37 suggests it plays a role in defending the lungs, particularly against intracellular bugs like TB

Practical Outcomes

  • While the data highlight LL‑37 as a potential marker of lung infection severity, the study doesn’t provide a way to boost or use the peptide directly. Biohackers might watch for future research on LL‑37‑raising supplements or diagnostics, but no immediate protocol change is recommended.

Summary

The study measured the natural antimicrobial peptide LL‑37 in blood and found it’s much higher in people with lung infections—especially tuberculosis—compared to healthy folks.

Abstract

The antimicrobial peptide cathelicidin LL-37 plays a role in the immune response in the course of lung infections; however, the exact role of LL-37 in defense mechanisms against bacteria within the respiratory tract is has not been precisely described. The aim of our study was to evaluate LL-37 concentrations in the serum of pulmonary tuberculosis (TB) patients, patients with pneumonia caused by Gram-positive and Gram-negative bacteria and to compare them with those of healthy subjects. Thirty TB patients, 30 patients with pneumonia caused by Gram-positive bacteria, 30 patients with pneumonia caused by Gram-negative bacteria, and 30 healthy control subjects were enrolled in the study. Serum LL-37 concentration was measured using an enzyme-linked immunosorbent assay (ELISA). The mean (± SEM) LL-37 concentration in patients with TB (13.94±5.13 ng/mL) was significantly higher than that in patients with Gram-positive bacteria-induced pneumonia (7.87±4.58 ng/mL, P=0.00077), in patients with Gram-negative bacteria-induced pneumonia (10.27±3.60 ng/mL, P=0.00730), and in control healthy subjects (1.75±0.71 ng/mL, P=0.00004). Our data suggest that cathelicidin LL-37 is an important element of host defense in the course of bacterial diseases within the respiratory tract, particularly when the infection is caused by an intracellular pathogen.

Study Information

Provider

pubmed

Year

2017

Date

2017-02-19T00:00:00.000Z

DOI

10.25011/cim.v40i1.28052